Effect of medical and surgical treatment of Barrett’s metaplasia

Table 1 Medical therapy and surgery for limiting progression and causing regression of Barrett’s esophagus n (%)

Publication	No. of patients	Follow-up (yr)	Adenocarcinoma	Dysplasia	Regression
Medical therapy
Hillman et al[13], 2004	279	4.7	7 (2.5)	5 (1.8)	NA
Cooper et al[9], 2006	188	5.1	3 (1.6)	6 (3.2)	NA
Nguyen et al[14], 2009	231	7.6	17 (7.4)	53 (23)	NA
Heath et al[10], 2007	82	0.9	6 (7.3)	9 (11)	34 (41)
Horwhat et al[11], 2007	67	3.8	2 (3.0)	21 (31)	13 (19)
Total	847	4.4	35 (4.1)	94 (11.1)	47 (31.5)
Surgery
Hofstetter et al[15], 2001	79	5.0	0	4 (5)	16 (20)
Bowers et al[16], 2002	64	4.6	0	1 (2)	31 (48)
Mabrut et al[17], 2003	13	3.8	0	0	6 (46)
Oelschlager et al[18], 2003	90	2.6	1 (1)	3 (3)	30 (33)
Desai et al[19], 2003	50	3.1	0	1 (2)	9 (18)
O'Riordan et al[20], 2004	57	3.8	2 (4)	2 (4)	14 (25)
Abbas et al[21], 2004	33	1.5	1 (3)	2 (6)	13 (39)
Zaninotto et al[22], 2005	35	2.3	0	0	6 (17)
Ozmen et al[23], 2006	37	1.6	0	1 (3)	6 (16)
Biertho et al[24], 2007	70	4.2	0	3 (4)	23 (33)
Biertho et al[25], 2009	23	4.5	0	0	14 (61)
Total	551	3.4	4 (0.7)	17 (3.4)	168 (30.5)

NA: Not applicable.

Table 2 Medical therapy vs surgery for Barrett’s esophagus n (%)

Publication	Treatments	PPI	Nissen	Progression PPI	Progression Nissen	Regression PPI	Regression Nissen	Study type
Gatenby et al[6], 2009	PPI vs Nissen	646	41	154 (24)	4 (10)	NA	NA	Cohort
Parrilla et al[28], 2003	H2RA/PPI vs Nissen	43	58	10 (23)	5 (9)	2 (5)	5 (9)	RCT
Rossi et al[29], 2006	PPI vs successful Nissen	19	16	NA	NA	12 (63)	16 (100)	Case comparison
Total		708	115	164 (23.8)	9 (9.1)	14 (22.6)	21 (28.4)

PPI: Proton pump inhibitor; H2RA: H2 receptor antagonist; RCT: Randomized controlled trial; NA: Not applicable.